ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset

Key Takeaways ANI Pharmaceuticals' 2025 revenue jumped 43.8% to $883.4M, led by Rare Disease and Brands growth.ANIP's Cortrophin Gel surged ~76% to $347.8M, becoming its primary specialty growth driver.ANI Pharmaceuticals expects retina recovery in 2026 after a 2025 reset amid reimbursement challenges.ANI Pharmaceuticals (ANIP) is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by Purified Cort ...